El interés en corto de Cytek Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cytek Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Cytek Biosciences (NASDAQ:CTKB) Bolsa, Informe de interés en corto

Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Cytek Biosciences Inc

Biotech

News

General

PYXS

Pyxis Oncology Granted FDA Fast Track Designation For PYX-201 Monotherapy In Recurrent Or Metastatic Head And Neck Cancer

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) reported quarterly earnings of $1.23 per share which beat the analyst consensus estimate of $1.16 by 6.03 percent. This is a 9.82 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $16.40 billion which beat the analyst consensus estimate of $16.20 billion by 1.26 percent. This is a 0.07 percent decrease over sales of $16.41 billion the same period last year.

Earnings

Earnings Beats

TJX Companies Q4 2025 Adj EPS $1.23 Beats $1.16 Estimate, Sales $16.40B Beat $16.20B Estimate

Oversea-Chinese Banking (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OVCHY#OTC">OVCHY</a>) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $0.41 by 439.02 percent. This is a 4.25 percent increase over earnings of $2.12 per share from the same period last year. The company reported quarterly sales of $2.56 billion which missed the analyst consensus estimate of $3.53 billion by 27.36 percent. This is a 4.82 percent increase over sales of $2.45 billion the same period last year.

Earnings Misses

OVCHY

Oversea-Chinese Banking Q4 GAAP EPS $2.21 Beats $0.41 Estimate, Sales $2.56B Miss $3.53B Estimate

Piper Sandler analyst Brent Bracelin upgrades ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) from Underweight to Neutral and raises the price target from $10 to $11.

Upgrades

Price Target

Analyst Ratings

Piper Sandler Upgrades ZoomInfo Technologies to Neutral, Raises Price Target to $11

Billionaire Ray Dalio cautioned investors in a recent podcast interview with Tucker Carlson saying that the development of artificial intelligence could risk totalitarian social control or even anarchy in the coming years.
Highlighting the unpredictability in the direction of AI's growth, Dalio anticipated a radically different world over the next five years.
What Happened: Dalio recently appeared on a podcast with Carlson on the latter's YouTube channel discussing the trends in the U.S. economy, debt crisis, stock market, and AI.
Discussing the various possibilities of using AI at a "molecular level," from solving medical issues to problems like inflation within an economy, Dalio said that AI was a "two-edged sword". The future could be shaped depending on who has access to and control of such AI tools, he said.
When asked if there was a way to avoid totalitarian social control through AI, Dalio said, "I think there&#8217;s a question of whether you can have social and totalitarian controls or maybe you just have anarchy."
Dalio believes that humanity will undergo an AI technology-induced "time warp," which will radically change the world in the next five years. He also added that quantum computing will be another innovation to look at.
"So the world five years from now is going to be a radically different world. And I don&#8217;t know what that&#8217;s going to look like when you go into the world of quantum computing and what quantum is like in so many different ways. It raises questions of, you know, what is that like?" said Dalio.
See Also: <a href="https://www.benzinga.com/25/02/43932776/mark-cuban-slams-fd-up-healthcare-system-blames-insurance-designed-deductibles-for-patient-bankruptcy">Mark Cuban Calls Deductibles &#8216;The Biggest Problem&#8217; in Healthcare: &#8216;System…Needs To Be Redesigned&#8217;</a>
Why It Matters: Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) launched ‘Majorana 1,' last week which is one of its kind quantum computing chip operating in a topological phase of matter. While Satya Nadella termed it a "physics breakthrough," he added that the launch of this chip could shorten the timeline of a possible quantum computing breakthrough.
Similarly, with DeepSeek's emergence, the competition in the AI industry has also intensified. Here is a list of AI and quantum computing-linked exchange-traded funds that investors could consider over the long term.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>ETF Name</td>
<td>YTD Performnace</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>iShares US Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>)</td>
<td>7.55%</td>
<td>0.90%</td>
</tr>
<tr>
<td>Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>)</td>
<td>-2.57%</td>
<td>17.89%</td>
</tr>
<tr>
<td>First Trust Dow Jones Internet Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDN#NYSE">FDN</a>)</td>
<td>0.80%</td>
<td>22.78%</td>
</tr>
<tr>
<td>iShares Expanded Tech Sector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGM#NYSE">IGM</a>)</td>
<td>-1.14%</td>
<td>20.91%</td>
</tr>
<tr>
<td>iShares Global Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IXN#NYSE">IXN</a>)</td>
<td>-0.66%</td>
<td>14.81%</td>
</tr>
<tr>
<td>Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>)</td>
<td>-1.93%</td>
<td>37.08%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. SPY was up 0.45% to $596.94, and QQQ advanced 0.75% to $517.16, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43936887/amazon-exceeds-walmart-q4-revenue-which-was-77x-lower-in-2000-took-25-years-contrary-to-jeff-bezos-10-year-overnight-success-statement-in-2018">Jeff Bezos Once Said &#8216;Overnight Success&#8217; Takes 10 Years. It Took Amazon 25 Years To Surpass Walmart&#8217;s Revenue</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Financing

Events

Markets

Tech

First Trust Dow Jones Internet Index Fund

FTEC

iShares Trust S&P Global Information Technology Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

MSFT

QTUM

Billionaire Ray Dalio Says AI Risks 'Totalitarian Control Or Anarchy' As It Could Reshape World In Next 5 Years: Here Are AI-Linked ETFs For Investors To Consider

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Buy and maintains $73 price target.

Reiteration

TARS

HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $73 Price Target

WIIM

Mablebear shares are trading lower after the company reported worse-than-expected Q4 revenue results.

NGVC

Natural Grocers Says It Expanded Private-Label Beverage Line With 100% Pure Organic Coconut Water

Anheuser-Busch InBev shares are trading higher after the company reported better-than-expected Q4 earnings and revenues.

Piper Sandler analyst Brent Bracelin maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Neutral and raises the price target from $270 to $290.

WDAY

Piper Sandler Maintains Neutral on Workday, Raises Price Target to $290

HC Wainwright &amp; Co. analyst Andres Maldonado maintains Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and lowers the price target from $40 to $36.

DAWN

HC Wainwright & Co. Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $36

Piper Sandler analyst Arvind Ramnani reiterates CCC Intelligent Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>) with a Neutral and lowers the price target from $13 to $11.

CCCS

Piper Sandler Reiterates Neutral on CCC Intelligent Solutions, Lowers Price Target to $11

First Quarter Fiscal 2026 Outlook
For the quarter ending April 26, 2025, the Company currently expects the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Contract revenues</td>
<td>$1.16 billion to $1.20 billion</td>
</tr>
<tr>
<td>Non-GAAP Adjusted EBITDA</td>
<td>$130.6 million to $140.6 million</td>
</tr>
<tr>
<td>Diluted Earnings per Common Share</td>
<td>$1.50 to $1.73</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;

Guidance

Dycom Industries Q1 Adj. EPS Outlook $1.50-$1.73 Vs, $1.81 Estimate

BLMN

Bloomin' Brands Sees FY25 Adj. EPS $1.20-$1.40 Vs $1.77 Estimate

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

ALNY

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Buybacks

VRSK

On Feb 19, Verisk Board Approved An Additional Share Repurchase Authorization Of Up To $1.0B

This preliminary assessment reveals possible recovery of an additional 20 million barrels of oil and 16 billion cubic feet of natural gas in the lower intervals of the San Andres. The Company's current, on-going waterflood program has proven reserves of 15 million barrels of oil and 3 billion cubic feet of natural gas.
This preliminary assessment is the first step in an ongoing, comprehensive, multi-disciplinary analysis of the field incorporating petrophysics, geology and engineering data. The preliminary assessment uses modern geoscience software and workflows, which will ultimately lead to a 3D geologic model incorporating extensive well control. The ongoing multi-disciplinary work indicates the presence of previously unrecognized intervals and is expected to identify new drilling locations.
The preliminary assessment indicates that the significant volumes of stranded oil present in the lower San Andres beneath the Company's approximately 13,700-acre position is best exploited by drilling 5,000 foot horizontal wells.

EONR

EON Resources Completes Preliminary Assessment, Identifying 20 Million Untapped Barrels In San Andres Formation

Piper Sandler analyst Brent Bracelin maintains Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) with a Overweight and raises the price target from $21 to $22.

BASE

Piper Sandler Maintains Overweight on Couchbase, Raises Price Target to $22

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $33 price target.

BCYC

HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $33 Price Target

Covestro (OTC:<a class="ticker" href="https://www.benzinga.com/stock/COVTY#OTC">COVTY</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.74) by 27.03 percent. This is a 440 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $3.60 billion which beat the analyst consensus estimate of $3.49 billion by 3.31 percent. This is a 5.48 percent decrease over sales of $3.81 billion the same period last year.

COVTY

Covestro Q4 EPS $(0.54) Beats $(0.74) Estimate, Sales $3.60B Beat $3.49B Estimate

Press Releases

Cytek Biosciences to Participate in Upcoming Investor Conferences

Cytek Biosciences Reports Third Quarter 2024 Financial Results

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

Cytek® Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards Program

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

Health Care

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

CTKB

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

ChromaDex

Codexis

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Cytek Biosciences

Interés en corto

Cytek Biosciences (NASDAQ:CTKB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL